Abstract
AB053. Assessing the predictive significance of tumor size in thymoma and thymic carcinoma: an analysis utilizing SEER database with propensity matching
Yipeng Yin1, Wei Wang2,3,4,5,6,7, Mingbo Tang1, Wei Liu1
1Department of Thoracic Surgery, The First Hospital of Jilin University, Changchun, China;
2Key Laboratory of Endocrine Glucose & Lipids Metabolism and Brain Aging, Ministry of Education, Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China;
3Shandong Key Laboratory of Endocrinology and Lipid Metabolism, Jinan, China;
4Shandong Institute of Endocrine and Metabolic Diseases, Jinan, China;
5“Chuangxin China” Innovation Base of Stem Cell and Gene Therapy for Endocrine Metabolic Diseases, Jinan, China;
6Shandong Engineering Laboratory of Prevention and Control for Endocrine and Metabolic Diseases, Jinan, China;
7Shandong Engineering Research Center of Stem Cell and Gene Therapy for Endocrine and Metabolic Diseases, Jinan, China
Correspondence to: Wei Liu, MD. Department of Thoracic Surgery, The First Hospital of Jilin University, 1 Xinmin Street, Chaoyang District, Changchun 130021, China. Email: l_w01@jlu.edu.cn.
Background: This study aims to clarify the impact of tumor size on the prognosis of patients diagnosed with thymoma and thymic carcinoma, leveraging data from a population-based registry.
Methods: Utilizing the Surveillance, Epidemiology, and End Results (SEER) database, this retrospective analysis identified patients diagnosed with thymoma and thymic carcinoma from 2000 to 2020. Propensity score matching was employed to mitigate potential statistical biases between groups categorized by tumor size (≤6.5 and >6.5 cm).
Results: The study included a total of 3,857 patients, comprising 2,688 with thymoma and 1,169 with thymic carcinoma. Multivariate analysis demonstrated that tumors ≤6.5 cm independently correlated with improved cancer-specific survival (CSS) (P=0.001; P<0.001) and overall survival (OS) (P<0.001; P<0.001) in both thymoma and thymic carcinoma cohorts. Subgroup analysis revealed that smaller tumors (≤6.5 cm) conferred survival benefits in patients with Masaoka-Koga stage IIB thymomas and stage III/IV thymic carcinomas (thymoma: CSS: P<0.001; OS: P<0.001; thymic carcinoma: CSS: P=0.02; OS: P=0.01). Additionally, World Health Organization (WHO) type A/AB/B1 and type B2/B3 thymomas with tumors ≤6.5 cm exhibited superior CSS (P=0.005; P<0.001) and OS (P=0.01; P=0.002).
Conclusions: Through propensity matching analysis utilizing the SEER database, this study underscores the prognostic significance of tumor size in both early-stage thymoma and advanced-stage thymic carcinoma, identifying a critical threshold of 6.5 cm. In the WHO classification, tumor size based on the cut-off value of 6.5 cm has a greater impact on the prognosis of type B2/B3 (high-risk group) than A/AB/B1 (low-risk group).
Keywords: Tumor size; thymoma; thymic carcinoma
Acknowledgments
Funding: None.
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://med.amegroups.com/article/view/10.21037/med-24-ab053/coif). The authors have no conflicts of interest to declare.
Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study did not require an ethical review. The data in this study can be obtained from the public SEER database [www.seer.cancer.gov (accessed on 10 February 2024)]. Permission to access the research data file in the SEER registry was received from the National Cancer Institute (NCI), USA.
Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
doi: 10.21037/med-24-ab053
Cite this abstract as: Yin Y, Wang W, Tang M, Liu W. AB053. Assessing the predictive significance of tumor size in thymoma and thymic carcinoma: an analysis utilizing SEER database with propensity matching. Mediastinum 2024;8:AB053.
